KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Assets (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Non-Current Assets for 13 consecutive years, with $72.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 55.48% to $72.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $552.0 million through Dec 2025, down 21.91% year-over-year, with the annual reading at $72.5 million for FY2025, 55.48% down from the prior year.
  • Non-Current Assets for Q4 2025 was $72.5 million at Xenon Pharmaceuticals, down from $127.7 million in the prior quarter.
  • The five-year high for Non-Current Assets was $319.8 million in Q4 2023, with the low at $7.4 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $119.4 million, with a median of $140.2 million recorded in 2023.
  • The sharpest move saw Non-Current Assets surged 1475.28% in 2022, then plummeted 55.48% in 2025.
  • Over 5 years, Non-Current Assets stood at $13.0 million in 2021, then soared by 1084.63% to $153.8 million in 2022, then soared by 107.89% to $319.8 million in 2023, then tumbled by 49.08% to $162.9 million in 2024, then tumbled by 55.48% to $72.5 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $72.5 million, $127.7 million, and $174.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.